DIVESTITURES (Details) (USD $)	3 Months Ended	9 Months Ended	3 Months Ended	0 Months Ended
Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Jun. 30, 2013 Medicis Buphenyl	Feb. 03, 2012 Dermik Clindamycin and benzoyl peroxide gel ("IDP-111") and Fluorouracil cream ("5-FU")
Asset acquisitions and disposition
Net cash proceeds					$ 19,000,000	$ 66,300,000
Gain or loss on transaction					0
Cost of alliance and service revenues	$ 14,353,000	$ 13,758,000	$ 44,241,000	$ 118,237,000		$ 69,200,000

Cost of generating revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Name:	us-gaap_CostOfServicesLicensesAndServices
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration